TrialBreast cancer research and treatment2015

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Antonio Llombart-Cussac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.